The treatment market for multiple myeloma across the
Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise
in value from $1.7 billion in 2014 to $2.8 billion by 2021, representing a
Compound Annual Growth Rate (CAGR) of 7.4%, according to new report.
The company’s latest report states that growth will
primarily be driven by the emergence of novel therapeutics that have
significantly improved clinical outcomes across all stages of the disease, as
well as the lack of generic competition in China, Japan and Australia.
According to Senior Analyst, expects the leading
brands, Revlimid, Velcade and Thalomid, to continue to perform strongly in the
APAC multiple myeloma treatment space, with minimal generic competition at
present.
Senior Analyst explains: “The only leading brand that
faces imminent generic challenge is the proteasome inhibitor Velcade, the
patent of which is expected to expire in China, Japan and Australia in 2015,
2018 and 2020, respectively. Generic versions of Velcade are already available
in India.
Furthermore, there are now several options in the
relapsed or refractory disease setting, which will also contribute to growth in
the APAC multiple myeloma therapeutics market by 2021. These drugs include
Pomalyst, which was approved in Australia and Japan in 2013, and Farydak, which
was approved in Japan earlier this year.
During the forecast period, these existing treatments
for multiple myeloma will be supplemented by new drugs, many of which will be
used in combination with the leading brands.
Senior Analyst continues: “Kyprolis will be launched
in the APAC region in the near future, Daratumumab has been trialed in
combination with Revlimid and dexamethasone, and elotuzumab has been trialed in
combination with Revlimid.
“These emerging multiple myeloma therapies are likely
to offer alternatives in the relapsed or refractory disease setting, in both
the second and third lines of treatment, further boosting APAC market growth.”
Other promising multiple myeloma pipeline drugs are
Zolinza, filanesib and plitidepsin. However, no clinical trial is registered
for these treatments in the APAC countries and they are only expected to launch
towards the end of forecast period, according to Publisher.
Multiple Myeloma Therapeutics in Asia-Pacific Markets
to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade,
Revlimid and Emerging Supplementary Treatments report provides analysis of the
multiple myeloma therapeutics space across the Asia-Pacific (APAC) countries of
India, China, Australia and Japan, with annualized market data from 2014 and
forecast to 2021. Key topics covered include treatment usage patterns, annual
therapy costs, and market growth projections for multiple myeloma treatment in
the APAC region.
This report was built using data and information
sourced from proprietary databases, primary and secondary research, and
in-house analysis conducted by Publisher’s team of industry experts.
Find more information Visit at:
http://mrr.cm/oXg
Find
all Healthcare
Reports at: http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.